Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study

BACKGROUND: This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with leiomyosarcoma. METHODS: Patients ≥18 years old with advanced liposarcoma or leiomyosarcoma, ECOG PS ≤2, and ≥2 prior treatment regimens were randomly assigned (1:1) to eribulin m...

Descripción completa

Detalles Bibliográficos
Autores principales: Blay, Jean-Yves, Schöffski, Patrick, Bauer, Sebastian, Krarup-Hansen, Anders, Benson, Charlotte, D’Adamo, David R., Jia, Yan, Maki, Robert G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738064/
https://www.ncbi.nlm.nih.gov/pubmed/31065111
http://dx.doi.org/10.1038/s41416-019-0462-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738064/
https://www.ncbi.nlm.nih.gov/pubmed/31065111
http://dx.doi.org/10.1038/s41416-019-0462-1

Ejemplares similares